JXL069

Last updated

JXL069
JXL069.svg
Clinical data
Drug class Mitochondrial pyruvate carrier (MPC) inhibitor
Identifiers
  • 3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-cyanoprop-2-enoic acid
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C20H11F6N3O2
Molar mass 439.317 g·mol−1
3D model (JSmol)
  • C1=CC2=C(N=C1)N(C=C2C=C(C#N)C(=O)O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
  • InChI=1S/C20H11F6N3O2/c21-19(22,23)14-4-11(5-15(7-14)20(24,25)26)9-29-10-13(6-12(8-27)18(30)31)16-2-1-3-28-17(16)29/h1-7,10H,9H2,(H,30,31)
  • Key:IGVIZFSCSSEYDA-UHFFFAOYSA-N

JXL069 is an experimental drug originally developed at the University of California, Los Angeles (UCLA) and licensed for development to Pelage Pharmaceuticals, which acts as a potent and selective mitochondrial pyruvate carrier (MPC) inhibitor that disrupts pyruvate import into mitochondria. It has been researched as a potential treatment for androgenetic alopecia and shows positive results in animal studies. Pelage Pharmaceuticals currently has a related candidate molecule PP405 in phase 2 clinical trials for hair loss formulated as a topical cream for the scalp. [1] [2] MPC inhibitors also have potential for the treatment of cancer, so a large number of related molecules have also been developed, of which JXL069 was among the most effective tested so far for treatment of hair loss. [3] [4] [5] [6] [7] [8] The drug is known to have been sold online in a grey market fashion for treatment of hair loss. [9] It has been believed to be PP405, but PP405 was said not to be JXL069 by Pelage Pharmaceuticals. [9]

See also

References

  1. ↑ "Regenerative Medicine in Action: Topical PP405 Shows Promise in Androgenetic Alopecia". The Dermatology Digest. 17 June 2025.
  2. ↑ Meara K (23 June 2025). "Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia". Dermatology Times.
  3. ↑ WO 2019/006359,Lowry WE, et al.,"Compositions and methods for modulating hair growth.",published 3 January 2019, assigned to The Regents Of The University Of California
  4. ↑ WO 2023/129854,Sun DL, et al.,"Compounds for treatment of hair loss.",published 6 July 2023, assigned to Pelage Pharmaceuticals, Inc.
  5. ↑ Liu X, Flores AA, Situ L, Gu W, Ding H, Christofk HR, et al. (February 2021). "Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss". Journal of Medicinal Chemistry. 64 (4): 2046–2063. doi:10.1021/acs.jmedchem.0c01570. PMC   8939290 . PMID   33534563.
  6. ↑ Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, et al. (February 2022). "Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening". Biomedicines. 10 (2): 365. doi: 10.3390/biomedicines10020365 . PMC   8962382 . PMID   35203575.
  7. ↑ Huang Y, Peng X, Zhang H, Pan M, Su X, Li G, et al. (November 2024). "Design, synthesis and biological evaluation of novel cyano-cinnamate derivatives as mitochondrial pyruvate carrier inhibitors". Bioorganic & Medicinal Chemistry Letters. 112 129923. doi:10.1016/j.bmcl.2024.129923. PMID   39134097.
  8. ↑ Politte H, Maram L, Elgendy B (February 2025). "Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications". Biomolecules. 15 (2): 223. doi: 10.3390/biom15020223 . PMC   11852594 . PMID   40001526.
  9. 1 2 Brown L (12 August 2025). "The Great Unbalding Draws Nearer". Intelligencer. Retrieved 24 October 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.